Levosalbutamol, Ambroxol Hcl & Guaiphenesin Drops

DROPS PRESENTATION:
Each ml contains:
Levosalbutamol Sulphate IP eq to Levosalbutamol IP 0.25 mg
Ambroxol HCL IP 7.5 mg
Guaiphenesin IP 12.5 mg

The product contains bronchodilators which dilates the respiratory track and secretolytic and mucolytic agent which helps in removal of the sputum formed., Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. Terbutaline is used for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Guaifenesin elicits an action to facilitate productive cough to manage chest congestion. Menthol mediates anesthetic properties and anti-irritating properties locally, thus it is widely used to relieve minor throat irritations.

• Cough
• Asthma
• Chest Tightness
• Chronic obstructive pulmonary disease (COPD)

Levosalbutamol acts by relaxing smooth muscle in the bronchial tubes to increase air flow and relieve acute shortness of breath. Levosalbutamol is a short-acting β2 adrenergic receptor agonist. β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.
Ambroxol is a mucolytic agent. Nitric oxide enhances the activation of soluble guanylate cyclase and cGMP accumulation. Ambroxol has been shown to inhibit the NO-dependent activation of soluble guanylate cyclase. Inhibition of NO-dependent activation of soluble guanylate cyclase can suppress the excessive mucus secretion.
Guaiphenesin is categorized as an expectorant that acts by enhancing the output of phlegm (sputum) and bronchial secretions via decreasing the adhesiveness and surface tension of such material. It may also act as an irritant to gastric vagal receptors, and recruit efferent parasympathetic reflexes that can elicit glandular exocytosis that is comprised of a less viscous mucus mixture.

The product is generally considered safe when taken in recommended doses however common side effects include stomach upset, nausea, vomiting, dizziness or headache.

Not be administered in patients with hypersensitive to sympathomimetic amines

• Guaiphenesin may interact with duloxetine, phenylephrine and albuterol.
• The risk or severity of hypertension can be increased when Levosalbutamol is combined with 2,5-Dimethoxy-4-ethylthioamphetamine and 1-benzylimidazole.
• The serum concentration of Ambroxol can be decreased when it is combined with Cenobamate, Pitolisant and Ritonavir.

Disclaimer:The data uploaded is made from content already available on internet.The company holds no right of it and is not responsible for any wrong information.